About Maravai LifeSciences Holdings,
Maravai LifeSciences Holdings, (MRVI) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $966.4M.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $966.4M
- EPS (TTM)
- $-0.90
- Revenue (TTM)
- $185.7M
- Free cash flow
- -$70.7M
- Profit margin
- -70.4%
- Shares outstanding
- 148M
Financial health: Weak1.7/10
1 strength, 7 concerns. Weakest points: debt to equity, net debt vs cash flow, return on equity and 4 more.
- Debt to equity: 1.37 (Concern, benchmark < 0.5) β Debt of 1.37x equity is high against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: β (Concern, benchmark < 4 years) β Carries $74.9M of net debt while free cash flow is negative, so the debt is not being repaid from the business.
- Current ratio: 6.60 (Strong, benchmark > 1.5) β Short-term assets cover 6.60x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
- Return on equity: -61.6% (Concern, benchmark > 15%) β Earns -61.6% on shareholder equity, well short of the > 15% mark.
- Gross margin: 18.3% (Concern, benchmark > 40%) β Keeps 18.3% of revenue after the direct cost of sales, well short of the > 40% mark.
- Net margin: -70.4% (Concern, benchmark > 10%) β Turns -70.4% of revenue into profit, well short of the > 10% mark.
- Free cash flow: -$70.7M (Concern, benchmark positive) β Burned $70.7M of cash after capital spending, so operations did not fund themselves. It has deteriorated over the last 4 years.
- Revenue growth: -28.3% (Concern, benchmark > 10%) β Revenue changed -28.3% year on year, well short of the > 10% mark.
- Earnings growth: 9.7% (Watch, benchmark > 10%) β Earnings changed 9.7% year on year, short of the > 10% mark.